Cancer Research in Switzerland - Krebsliga Schweiz

More documents

Recommendations

Info

62 Romero Pedro | OCS 02011022007 | CHF 173,600.– Division d’oncologie clinique, Centre Ludwig de recherche sur le cancer, Lausanne Impact of lentiviral cancer vaccines on the anti-tumor T-cell response in vivo Rüegg Curzio | OCS 02020022007 | CHF 275,600.– Division de pathologie expérimentale, Université de Fribourg, Fribourg Role of integrins and Cyr61/CCN1 in tumor metastasis: Unraveling mechnisms and development of novel integrin inhibitors Rufer Nathalie | OCS 01995022007 | CHF 204,500.– Centre Ludwig de recherche sur le cancer, Université de Lausanne, Lausanne Defining molecular, structural and functional T-cell receptor properties of melanoma-specific human CD8 + T lymphocytes Ruiz i Altaba Ariel | OCS 01857022006 | CHF 321,900.– Département de génétique médicale et de développement, Faculté de médecine, Université de Genève, Genève Determination of the extent of participation of the sonic hedgehog-GLI signalling pathway in human gliomas and in their cancer stem cells Schär Primo | OCS 02193022008 | CHF 283,400.– Institut für Biochemie und Genetik, Departement Biomedizin, Universität Basel, Basel The role of thymine DNA glycosylase in the maintenance of genetic and epigenetic stability and the suppression of tumorigenesis Continuation of the project: Schär Primo | OCS 01868022006 | CHF 210,800.– Institut für Biochemie und Genetik, Departement Biomedizin, Universität Basel, Basel Clarification of newly emerging roles of DNA repair in mediating the cytotoxicity of 5-fluorouracil and in the maintenance of epigenetic stability Schübeler Dirk | KLS 01865022006 | CHF 179,500.– Friedrich Miescher Institut für biomedizinische Forschung (FMI), Basel Role and plasticity of DNA methylation in stem cell pluripotency and cancer Schwaller Jürg | OCS 01830022006 | CHF 228,100.– Forschungsgruppe Kinderleukämie, Departement Biomedizin, Universitätsspital Basel, Basel PIM serine/threonine kinases as potential therapeutic targets in human hematological malignancies Skoda Radek C. | OCS 01742082005 | CHF 339,000.– Forschungsgruppe experimentelle Hämatologie, Departement Biomedizin, Universitätsspital Basel, Basel Pathogenesis of myeloproliferative disorders Stamenkovic Ivan | OCS 01656022005 | CHF 173,900.– Institut universitaire de pathologie de Lausanne (IUP), Centre hospitalier universitaire vaudois (CHUV), Lausanne Analysis of the molecular mechanisms underlying the pathogenesis of EWING’S family tumors Suter Beat | OCS 01834022006 | CHF 243,000.– Institut für Zellbiologie, Universität Bern, Bern Control of the cell cycle function of Xpd and Cdk7 Tschan Mario P. | OCS 01823022006 | CHF 203,800.– Medizinische Onkologie/Hämatologie, Departement für klinische Forschung, Universität Bern, Bern Regulation of the DMP1-ARF-p53 tumor suppressor pathway in normal and leukemic hematopoiesis Walker Paul R. | OCS 01754082005 | CHF 269,200.– Centre d’oncologie, Hôpitaux universitaires de Genève (HUG), Genève Exploration of intracerebral immune responses in a spontaneous astrocytoma model and their exploitation in novel cancer therapies Wymann Matthias | OCS 01924082006 | CHF 293,500.– Forschungsgruppe Krebs und Immunbiologie, Departement Biomedizin, Universität Basel, Basel Phosphoinositide 3-kinases in melanoma
Zaugg Kathrin | OCS 02009022007 | CHF 195,500.– Labor für angewandte RadioOnkologie, UniversitätsSpital Zürich, Zürich Elucidating the role of the hypoxia-protective gene CPT1C in carcinogenesis Continuation in the project: Zaugg Kathrin | KLS 02569022010 | CHF 78,000.– Labor für angewandte RadioOnkologie, UniversitätsSpital Zürich, Zürich Elucidating the role of the hypoxia-protective gene CPT1C (Carnitine Palmitoyl-transferase 1C) in carcinogenesis Duration: 01.05.2010 – 01.05.2011 Basic biomedical research Presentation of completed research projects from July 2008 to December 2010 BallmerHofer Kurt | Structural and functional analysis of ligand-mediated activation of VEGF receptor 2; identification and characterization of structural motifs for the development of new receptor inhibitory drugs for anti-vascular tumor therapy (OCS 02100082007) Vascular Endothelial Growth Factors (VEGFs) constitute a family of proteins that regulate blood and lymphatic vessel development. Vessel formation and the maintenance of proper vessel organization are absolutely required for sustaining organ function in higher organisms. Aberrant vessel formation is associated with various diseases, such as arteriosclerosis, retinopathies, lymphoproliferative or rheumatoid disease, and in tumour growth where newly formed vessels allow cancer cells to grow more rapidly and to disseminate into the entire body. Tumour vascularization is a hallmark of many types of highly aggressive malignancies, such as breast, colon and stomach cancer. VEGFs bind to receptors expressed on the surface of cells and thereby activate their target cells to migrate, proliferate and ultimately to form new vessels. VEGF binding to cell surface exposed receptors induces changes in receptor structure that lead to receptor activation thereby giving rise to the generation of signals transmitted across the cell membrane to the intracellular milieu of the cell. We investigated the molecular mechanism of VEGF receptor activation with the aim to develop new receptor inhibitors applicable for the treatment of disease associated with aberrant vessel formation. Studying the structure of VEGF receptors and VEGFreceptor complexes, we found that VEGF binding drastically alters the threedimensional structure of the receptor. These structural changes are re sponsible for receptor activation and give rise to signals that promote the formation of new vessels. We investigated VEGF receptors using electron microscopy, Xray crystallography and small angle solution scattering techniques. The structural and functional information gained in this project was used to develop a comprehensive molecular model of receptor function that was essential for further progress in the development of new receptor antagonists for future medical applications. Based on the newly gained insights into the activation mechanism of VEGF receptors, we developed new antibodylike molecules to block receptor activation. In a follow up study we are now investigating the potential of these new molecular tools to block tumour growth in an animal model. Project coordinator Prof. Dr. Kurt BallmerHofer Laboratory of Biomolecular Research Molecular Cell Biology Paul Scherrer Institut Bldg. OFLC 102 CH5232 VilligenPSI Phone +41 (0)56 310 41 65 Fax +41 (0)56 310 52 88 kurt.ballmer@psi.ch 63
Page 1 and 2:
Cancer Research in Switzerland A pu
Page 3 and 4:
Cancer Research in Switzerland
Page 5 and 6:
Basic biomedical research 55 Cancer
Page 7 and 8:
policy work and was in charge of de
Page 9 and 10:
The main focus of the research fund
Page 11 and 12:
gramme research funding decreased b
Page 13 and 14: Table 2 Distribution of funds for i
Page 15 and 16: Funding patient-centred research Pa
Page 17 and 18: value was not clearly discernible.
Page 19 and 20: New organization of the Foundation
Page 21 and 22: The board of the Foundation Cancer
Page 23 and 24: The president of the Scientific Com
Page 25 and 26: Prof. Martin Pruschy, PhD Departmen
Page 27 and 28: Swartz wants to find out how tumour
Page 29 and 30: The scientific and medical research
Page 31 and 32: 3. The original order/sequence of t
Page 33 and 34: As a federation, the Cancer League
Page 35 and 36: List of funded research projects, i
Page 37 and 38: Zippelius Alfred | 2009: CHF 100,00
Page 39 and 40: Kridel Robert | 2010: CHF 100,000.-
Page 41 and 42: Thurgau Cancer League Biotechnologi
Page 43 and 44: Weller Michael | 2010: CHF 65,828.-
Page 45 and 46: manageable funding of individual pr
Page 47 and 48: enhances breast cancer cell motilit
Page 49 and 50: Rüegg Curzio et al. | Tumor-mediat
Page 51 and 52: International Clinical Cancer Resea
Page 53 and 54: in PHIV were shown for Hodgkin’s
Page 55: Zucca Emanuele et al. | Internation
Page 58 and 59: 56 “hierarchical structure” of
Page 60 and 61: 58 the attempt should be made to st
Page 62 and 63: 60 Gönczy Pierre | KLS 0202402
Page 66 and 67: 64 Beermann Friedrich | In vivo scr
Page 68 and 69: 66 Christofori Gerhard | Podoplanin
Page 70 and 71: 68 Frei Christian | The function of
Page 72 and 73: 70 cell, this novel mechanism serve
Page 74 and 75: 72 Results The induction of viral p
Page 76 and 77: 74 Hübscher Ulrich | Repair of oxi
Page 78 and 79: 76 Methods and experimental approac
Page 80 and 81: 78 of cMyc and/or NMyc and demo
Page 82 and 83: 80 In summary, this work improves o
Page 84 and 85: 82 Pruschy Martin | Microtubule int
Page 86 and 87: 84 Renner Christoph | Selective inh
Page 88 and 89: 86 Goal Here we build on these obse
Page 90 and 91: 88 by TDG prevents efficient downst
Page 92 and 93: 90 To address these questions, we a
Page 94 and 95: 92 Translational relevance The resu
Page 96 and 97: 94 Grünberg Jürgen | KFS 025460
Page 98 and 99: 96 Tschan Mario P. | KFS 0248608
Page 100 and 101: 98 Boyman Onur | Preclinical testin
Page 102 and 103: 100 Constam Daniel | Role of activi
Page 104 and 105: 102 this study we will examine the
Page 106 and 107: 104 Janscak Pavel | Study of the ro
Page 108 and 109: 106 Müller Anne | The molecular pa
Page 110 and 111: 108 Radtke Freddy | The role of Not
Page 112 and 113: 110 Schär Primo | DNA repair, epig
Page 114 and 115:
112 In this project we will investi
Page 116 and 117:
114
Page 118 and 119:
116 and Research). Other financial
Page 120 and 121:
118 be totally unaffordable for aca
Page 122 and 123:
120 Clinical research List of compl
Page 124 and 125:
122 Hunger Robert E. | OCS 02262-08
Page 126 and 127:
124 Clinical research Presentation
Page 128 and 129:
126 Benhattar Jean | Identification
Page 130 and 131:
128 Bertoni Francesco | Genome-wide
Page 132 and 133:
130 Interpretation ESA treatment in
Page 134 and 135:
132 Our results could pave the way
Page 136 and 137:
134 new drugs that specifically tar
Page 138 and 139:
136 slides in two different concent
Page 140 and 141:
138 Conclusions A strong network of
Page 142 and 143:
140 tions introduced to ARE motifs
Page 144 and 145:
142 Müller Beatrice U. | The maste
Page 146 and 147:
144 A novel method was developed fo
Page 148 and 149:
146 (SAKK 35-98) the Swiss Group fo
Page 150 and 151:
148 Timmermann Beate | Prospective
Page 152 and 153:
150 recurrence of the disease, we a
Page 154 and 155:
152 Zucca Emanuele | A prospective
Page 156 and 157:
154 Heinimann Karl | KFS 02489-08-2
Page 158 and 159:
156 Riggi Nicolò | BIL KFS 02717-0
Page 160 and 161:
158 activity at the single cell lev
Page 162 and 163:
160 Our research projects aim at un
Page 164 and 165:
162 Körner Meike | In vitro evalua
Page 166 and 167:
164 Nadal David | Is endemic Burkit
Page 168 and 169:
166 (> 50.000/patient). For their a
Page 170 and 171:
168 Zeller Rolf | Functional analys
Page 172 and 173:
170
Page 174 and 175:
172 area of health services researc
Page 176 and 177:
174 The financing of palliative car
Page 178 and 179:
176 National Strategy for Palliativ
Page 180 and 181:
178 Psychosocial research List of c
Page 182 and 183:
180 Within the patient group, level
Page 184 and 185:
182 Further, the results suggest th
Page 186 and 187:
184 It is in this context that the
Page 188 and 189:
186 Recommendation Female spouses o
Page 190 and 191:
188 Psychosocial research Presentat
Page 192 and 193:
190 rates communication skills rema
Page 195 and 196:
Epidemiological research Epidemiolo
Page 197 and 198:
data from cancer registries. In the
Page 199 and 200:
The importance of cancer registries
Page 201 and 202:
Ess Silvia | Patterns of care and s
Page 203 and 204:
Epidemiological research List of ap
Page 205 and 206:
Impact This work will serve as the
Page 207 and 208:
Thürlimann Beat | Management of br
show all

Cancer Research in Switzerland - Krebsliga Schweiz

Create successful ePaper yourself

Delete template?

Save as template?